Suppr超能文献

肿瘤来源外泌体的微小RNA特征作为卵巢癌的诊断生物标志物

MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.

作者信息

Taylor Douglas D, Gercel-Taylor Cicek

机构信息

Department of Obstetrics, Gynecology, and Women's Health, University of Louisville School of Medicine, Louisville, KY 40202, USA.

出版信息

Gynecol Oncol. 2008 Jul;110(1):13-21. doi: 10.1016/j.ygyno.2008.04.033.

Abstract

OBJECTIVES

Most ovarian cancer patients are diagnosed at an advanced stage (67%) and prospects for significant improvement in survival reside in early diagnosis. While expression patterns of a recently identified biomarker family, microRNA, appear to be characteristic of tumor type and developmental origin, microRNA profiling has been limited to tissue specimens. Tumors actively release exosomes into the peripheral circulation and we now demonstrate the association of microRNAs with circulating tumor-derived exosomes.

METHODS

Circulating tumor exosomes were isolated using a modified MACS procedure with anti-EpCAM. Initially, microRNA profiles of ovarian tumors were compared to those of tumor exosomes isolated from the same patients. Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.

RESULTS

MicroRNA from ovarian tumor cells and exosomes from the same patients were positive for 218 of 467 mature microRNAs analyzed. The levels of the 8 specific microRNAs were similar between cellular and exosomal microRNAs (exhibiting correlations from 0.71 to 0.90). While EpCAM-positive exosomes were detectable in both patients with benign ovarian disease and ovarian cancer, exosomal microRNA from ovarian cancer patients exhibited similar profiles, which were significantly distinct from profiles observed in benign disease. Exosomal microRNA could not be detected in normal controls.

CONCLUSIONS

These results suggest that microRNA profiling of circulating tumor exosomes could potentially be used as surrogate diagnostic markers for biopsy profiling, extending its utility to screening asymptomatic populations.

摘要

目的

大多数卵巢癌患者在晚期被诊断出来(67%),而生存显著改善的前景在于早期诊断。虽然最近鉴定出的生物标志物家族——微小RNA的表达模式似乎具有肿瘤类型和发育起源的特征,但微小RNA分析一直局限于组织标本。肿瘤会主动将外泌体释放到外周循环中,我们现在证明了微小RNA与循环肿瘤来源的外泌体之间的关联。

方法

使用改良的抗EpCAM磁性激活细胞分选程序分离循环肿瘤外泌体。最初,将卵巢肿瘤的微小RNA谱与从同一患者分离的肿瘤外泌体的谱进行比较。比较了先前已证明具有诊断意义的8种微小RNA(miR-21、miR-141、miR-200a、miR-200c、miR-200b、miR-203、miR-205和miR-214)在良性疾病女性和不同阶段卵巢癌患者血清标本中分离的外泌体中的水平。

结果

在分析的467种成熟微小RNA中,来自卵巢肿瘤细胞的微小RNA和来自同一患者的外泌体中有218种呈阳性。细胞微小RNA和外泌体微小RNA中8种特定微小RNA的水平相似(相关性在0.71至0.90之间)。虽然在良性卵巢疾病患者和卵巢癌患者中均可检测到EpCAM阳性外泌体,但卵巢癌患者的外泌体微小RNA表现出相似的谱,这与在良性疾病中观察到的谱明显不同。在正常对照中未检测到外泌体微小RNA。

结论

这些结果表明,循环肿瘤外泌体的微小RNA分析可能潜在地用作活检分析的替代诊断标志物,将其应用扩展到无症状人群的筛查。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验